Biopharma is rebounding across rare disease, oncology and neuroscience. Here, Cytokinetics achieved a rare milestone: a first ...
Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, ...
Eli Lilly’s run of near-weekly acquisitions still shows no sign of letting up, with the Big Pharma now buying Ajax ...
The 552 million pounds ($747 million) raised by British biotechs in the first quarter of the year has been hailed as a “sign ...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for ...
Discover the best biotech ETFs to diversify your portfolio, gain exposure to cutting-edge biotech innovations, and reduce risk in a volatile sector.
Seaport will use the funds for its neuropsychiatric drug pipeline, while Hemab will focus on bleeding disorder medicines.
The promise of a better pan-RAS inhibitor Erasca has been described as the poor man’s Revolution Medicines. Impoverished ...
MustardSeed's 90-Day TrialReady Program gives early-stage biotech teams the integrated infrastructure they need to reach IND on time and in control. PHILADELPHIA, PA / ACCESS Newswire / April 28, 2026 ...
24/7 Wall St. on MSN
LABU could rip higher if biotech finally gets its long-awaited breakout
Quick Read Direxion Daily S&P Biotech Bull 3X Shares (LABU) delivered 235% returns over the past year versus 65% for the ...
Legend Biotech Corporation looks like a J&J acquisition target as Carvykti sales surge and Phase 2 data impress. Click for ...
Jyong Biotech Ltd. (Nasdaq: MENS) (the 'Company” or 'Jyong Biotech”), a science-driven biotechnology company dedicated to the development and commercialization of innovative plant-derived therapeutics ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results